TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03550599

Intervention type: OTHER
Intervention: Patients accessing to Radiotherapy Unit
Description: No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
Study: NCT03114683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1
Description: IBI308 200mg/3 weeks
Study: NCT01697917

Intervention type: OTHER
Group type: OTHER
Intervention: Total Gastrectomy or Proximal Gastrectomy
Study: NCT00102609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
Study: NCT00570050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent / Insulin
Description: Diluent (4 Weeks ) / Intranasal insulin (4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent / Insulin
Description: Diluent (4 Weeks ) / Intranasal insulin (4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin / Diluent
Description: Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin / Diluent
Description: Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
Study: NCT02729532

Intervention type: DEVICE
Intervention: Xpert
Description: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
Study: NCT02633904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotomy
Description: Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-osteotomy
Description: Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
Study: NCT03426891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
Study: NCT02621125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fertilix
Description: daily supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02348762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cysteine (as n-acetylcysteine) and Glycine
Description: Older subjects will be studied before and after receiving cysteine and glycine
Study: NCT04343638

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional nociception control
Description: While Intraoperative opioid will be administered by conventional clinical practice in control arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI monitor guided nociception control
Description: The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
Study: NCT01599715

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Instructional DVD
Description: Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
Study: NCT03426891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
Study: NCT01599715

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bladder Health Class
Description: Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
Study: NCT02829788

Intervention type: OTHER
Intervention: Non interventional
Description: Peroperative data collection
Study: NCT02911415

Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.

Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
Study: NCT00728689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ST-246 Days 1 - 3
Description: First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ST-246 Days 1 - 3
Description: First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ST-246 Days 11 - 13
Description: Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Study: NCT03931031

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
Study: NCT00594360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise on Prescription
Description: Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
Study: NCT00888446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAC09

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formulation buffer
Description: Sterile isotonic buffered salt solution
Study: NCT02202954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-rehabilitation Contract
Description: In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary.
Study: NCT01508715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder resistive exercise
Description: Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder resistive exercise
Description: Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks.
Study: NCT02076178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 744 Tablet
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 744 LA Injection
Description: Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Microcrystalline cellulose, Opadry film-coating, white OY-S-28876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Sterile saline 0.9% Sodium Chloride Injection
Study: NCT02521220

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline 2 times daily 3 gram (6g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 2 times daily 3 gram (6g/day)
Study: NCT00728689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ST-246 Days 11 - 13
Description: Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Study: NCT02461758

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Standard dose Influenza vaccine (SDIV)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Standard dose Influenza vaccine (SDIV)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Standard dose Influenza vaccine (SDIV)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High dose influenza vaccine (HDIV)
Study: NCT03271086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The StressEraser
Description: The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The StressEraser
Description: The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe2Relax
Description: Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder text messages
Description: Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
Study: NCT00782990

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment: TVT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment: colposuspension
Study: NCT02516137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blunt needle placement
Description: Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hamstring stretching exercise
Description: Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard hamstring stretching exercise
Description: Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard hamstring stretching exercise
Description: Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
Study: NCT03430284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring and management
Description: Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.

Intervention type: OTHER
Group type: OTHER
Intervention: General treatment
Description: General treatment is carried out based on the device from the general practitioners at present.
Study: NCT00993577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
Study: NCT00887809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT04356898

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03023397

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Der f
Description: Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Der f
Description: Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Der f
Description: Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
Study: NCT03699514

Intervention type: DEVICE
Intervention: Brain Network Activation (BNA™) technology
Description: The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only.